238 related articles for article (PubMed ID: 35224495)
1. An overview of the development of EED inhibitors to disable the PRC2 function.
Liu KL; Zhu K; Zhang H
RSC Med Chem; 2022 Jan; 13(1):39-53. PubMed ID: 35224495
[TBL] [Abstract][Full Text] [Related]
2. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL
Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670
[TBL] [Abstract][Full Text] [Related]
3. Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.
Chen H; Gao S; Li J; Liu D; Sheng C; Yao C; Jiang W; Wu J; Chen S; Huang W
Oncotarget; 2015 May; 6(15):13049-59. PubMed ID: 25944687
[TBL] [Abstract][Full Text] [Related]
4. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
[TBL] [Abstract][Full Text] [Related]
5. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns.
Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW
Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628
[TBL] [Abstract][Full Text] [Related]
6. Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer.
Martin MC; Zeng G; Yu J; Schiltz GE
J Med Chem; 2020 Dec; 63(24):15344-15370. PubMed ID: 33283516
[TBL] [Abstract][Full Text] [Related]
7. Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment.
Cook N; Chen J; Zhou J; Wu D
Curr Top Med Chem; 2021; 21(31):2771-2777. PubMed ID: 34544341
[TBL] [Abstract][Full Text] [Related]
8. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
[TBL] [Abstract][Full Text] [Related]
9. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
[TBL] [Abstract][Full Text] [Related]
10. Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
Neff T; Sinha AU; Kluk MJ; Zhu N; Khattab MH; Stein L; Xie H; Orkin SH; Armstrong SA
Proc Natl Acad Sci U S A; 2012 Mar; 109(13):5028-33. PubMed ID: 22396593
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-323-3p regulates the activity of polycomb repressive complex 2 (PRC2) via targeting the mRNA of embryonic ectoderm development (Eed) gene in mouse embryonic stem cells.
Zhang Y; Teng F; Luo GZ; Wang M; Tong M; Zhao X; Wang L; Wang XJ; Zhou Q
J Biol Chem; 2013 Aug; 288(33):23659-65. PubMed ID: 23821546
[TBL] [Abstract][Full Text] [Related]
12. Mutations in genes encoding polycomb repressive complex 2 subunits cause Weaver syndrome.
Imagawa E; Higashimoto K; Sakai Y; Numakura C; Okamoto N; Matsunaga S; Ryo A; Sato Y; Sanefuji M; Ihara K; Takada Y; Nishimura G; Saitsu H; Mizuguchi T; Miyatake S; Nakashima M; Miyake N; Soejima H; Matsumoto N
Hum Mutat; 2017 Jun; 38(6):637-648. PubMed ID: 28229514
[TBL] [Abstract][Full Text] [Related]
13. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.
Qi W; Zhao K; Gu J; Huang Y; Wang Y; Zhang H; Zhang M; Zhang J; Yu Z; Li L; Teng L; Chuai S; Zhang C; Zhao M; Chan H; Chen Z; Fang D; Fei Q; Feng L; Feng L; Gao Y; Ge H; Ge X; Li G; Lingel A; Lin Y; Liu Y; Luo F; Shi M; Wang L; Wang Z; Yu Y; Zeng J; Zeng C; Zhang L; Zhang Q; Zhou S; Oyang C; Atadja P; Li E
Nat Chem Biol; 2017 Apr; 13(4):381-388. PubMed ID: 28135235
[TBL] [Abstract][Full Text] [Related]
14. Inner workings and regulatory inputs that control Polycomb repressive complex 2.
O'Meara MM; Simon JA
Chromosoma; 2012 Jun; 121(3):221-34. PubMed ID: 22349693
[TBL] [Abstract][Full Text] [Related]
15. Molecular and functional mapping of EED motifs required for PRC2-dependent histone methylation.
Montgomery ND; Yee D; Montgomery SA; Magnuson T
J Mol Biol; 2007 Dec; 374(5):1145-57. PubMed ID: 17997413
[TBL] [Abstract][Full Text] [Related]
16. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer.
Kim W; Bird GH; Neff T; Guo G; Kerenyi MA; Walensky LD; Orkin SH
Nat Chem Biol; 2013 Oct; 9(10):643-50. PubMed ID: 23974116
[TBL] [Abstract][Full Text] [Related]
17. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
18. Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2).
Xu C; Bian C; Yang W; Galka M; Ouyang H; Chen C; Qiu W; Liu H; Jones AE; MacKenzie F; Pan P; Li SS; Wang H; Min J
Proc Natl Acad Sci U S A; 2010 Nov; 107(45):19266-71. PubMed ID: 20974918
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Polycomb Repressive Complex 2 activity reduces trimethylation of H3K27 and affects development in Arabidopsis seedlings.
Ruta V; Longo C; Boccaccini A; Madia VN; Saccoliti F; Tudino V; Di Santo R; Lorrai R; Dello Ioio R; Sabatini S; Costi R; Costantino P; Vittorioso P
BMC Plant Biol; 2019 Oct; 19(1):429. PubMed ID: 31619182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
